Preclinical and clinical studies have demonstrated the efficacy of Tivozanib in inhibiting tumor angiogenesis and delaying disease progression in RCC patients, highlighting its therapeutic potential as a VEGFR-2 inhibitor [15,16,17]. This evidence concerns the gene KDR and neoplasm.